Needham & Company LLC Issues Pessimistic Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its price objective lowered by Needham & Company LLC from $870.00 to $600.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside of 38.28% from the company’s previous close.

AXON has been the subject of a number of other reports. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. The Goldman Sachs Group lowered their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Morgan Stanley dropped their target price on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Finally, Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Fifteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $786.43.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $433.91 on Friday. The company’s fifty day moving average is $544.63 and its two-hundred day moving average is $636.33. Axon Enterprise has a 52-week low of $396.41 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The firm has a market capitalization of $34.24 billion, a price-to-earnings ratio of 137.31, a P/E/G ratio of 13.07 and a beta of 1.48.

Insider Activity at Axon Enterprise

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total value of $55,063.00. Following the completion of the transaction, the director directly owned 1,316 shares of the company’s stock, valued at $724,629.08. This represents a 7.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 48,040 shares of company stock valued at $27,249,338. 4.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Creative Financial Designs Inc. ADV acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at $28,000. Stone House Investment Management LLC acquired a new position in shares of Axon Enterprise during the third quarter valued at $29,000. New Millennium Group LLC bought a new position in Axon Enterprise in the third quarter valued at about $29,000. Sound Income Strategies LLC increased its position in Axon Enterprise by 550.0% in the fourth quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 44 shares during the period. Finally, Camelot Portfolios LLC bought a new stake in Axon Enterprise during the 4th quarter worth about $30,000. Institutional investors own 79.08% of the company’s stock.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Needham kept a Buy rating and cites strong bookings momentum and an expanding ecosystem, supporting medium-term growth expectations. Axon: Strong Bookings Momentum and Expanding Ecosystem Drive Sustained Growth and Buy Rating
• Positive Sentiment: Recent market-coverage pieces highlighted a trading-day gain (a prior session rise of ~2.6%), showing there remains near-term buying interest on positive news flow. Why the Market Dipped But Axon Enterprise (AXON) Gained Today
• Neutral Sentiment: Wall Street projections for AXON’s Q4 (Dec‑2025) revenues, bookings and margins are now widely circulated; these estimates will drive the next big move when quarterly results and guidance arrive. Insights Into Axon (AXON) Q4: Wall Street Projections for Key Metrics
• Neutral Sentiment: Several “trending” and company‑profile summaries are circulating, increasing retail attention but not adding new fundamental catalysts by themselves. Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Reported short‑interest data in the feeds appears to be erroneous/zeroed out (no actionable signal); ignore until accurate figures are posted by exchanges.
• Negative Sentiment: Multiple insiders sold about US$43M of AXON stock recently — a near‑term negative for sentiment as investors often view sizeable insider selling as cautionary. Axon Enterprise Insiders Sell US$43m Of Stock, Possibly Signalling Caution
• Negative Sentiment: Needham lowered its price target from $870 to $600 — while the Buy rating remains, the reduced target trims upside and can weigh on investor sentiment and momentum. Benzinga Coverage of Needham Price Target Change

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.